Abstract

Completion Axillary Lymph Node Dissection for Breast Cancer: Immediate Versus Delayed Versus None

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Multidisciplinary considerations in the treatment of triple-negative breast cancer.
Tari A King ... Elizabeth S Frank
CA: a cancer journal for clinicians | VOL. 70
Tari A King, et. al.Tari A King ... Elizabeth S Frank
28 Sep 2020
Does a positive sentinel lymph node always require completion dissection?
Mahmoud El-Tamer ... Catherine Pesce
Breast Cancer Management | VOL. 1
Mahmoud El-Tamer, et. al.Mahmoud El-Tamer ... Catherine Pesce
01 Jul 2012
Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on Clinical Management of the Axilla in Older Breast Cancer Patients: A SEER-Medicare Analysis
Marquita Decker ... Nicole M Steffens
Annals of Surgical Oncology | VOL. 20
Marquita Decker, et. al.Marquita Decker ... Nicole M Steffens
20 Aug 2013
Is axillary dissection unnecessary in patients with a positive sentinel lymph node?
Masakuni Noguchi
Breast Cancer | VOL. 19
Masakuni NoguchiMasakuni Noguchi
12 Apr 2012
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers